In vitro diagnostics specialist bioMérieux has acquired Accellix, a U.S.-based company specializing in rapid, automated flow cytometry solutions for cell and gene therapy quality control.
The transaction, valued at approximately $41 million (€35 million), will strengthen bioMérieux’s pharma quality control capabilities and enable the company to better support the growing advanced therapy market. Accellix employs approximately 70 people across two locations: San José, California and Jerusalem, Israel.
The deal builds on a 2020 cell and gene therapy collaboration between the companies, with bioMérieux now increasing its stake in Accellix from roughly 10% to 100%. bioMérieux was already the exclusive distributor of Accellix products locally in the Asia-Pacific region, and globally for some cell and gene therapy leaders. Post-acquisition, bioMérieux will expand its portfolio in advanced therapies quality control solutions, by testing raw material and in-process quality as well as product efficacy and safety.
Accellix has developed a compact flow cytometry platform that the company says delivers results in under 30 minutes, enabling real-time quality control during cell therapy manufacturing. By simplifying complex workflows and reducing turnaround time, the platform helps manufacturers meet stringent regulatory requirements.
Subscribe to our e-Newsletters
Stay up to date with news, articles and insights relevant to cell and gene therapy development and manufacturing. Plus, get special offers from Cell & Gene Therapy Review delivered right to your inbox!
Sign up now!